Theratech begins female testosterone patch trial:
This article was originally published in Clinica
Theratech has begun a Phase II study of its testosterone patch to treat younger women who have undergone hysterectomy and suffer from depleted sexual function. The study will use the patch to administer small doses of testosterone, that would normally be released by the ovaries. It will evaluate if testosterone therapy restores the patients' sexual desire, frequency and satisfaction. Theratech, based in Salt Lake City, Ohio, estimates that as many as 10 million women living in the US and Europe have undergone hysterectomy.